Literature DB >> 27091578

The inhibitory mechanism of a fullerene derivative against amyloid-β peptide aggregation: an atomistic simulation study.

Yunxiang Sun1, Zhenyu Qian, Guanghong Wei.   

Abstract

Alzheimer's disease (AD) is associated with the pathological self-assembly of amyloid-β (Aβ) peptides into β-sheet enriched fibrillar aggregates. Aβ dimers formed in the initial step of Aβ aggregation were reported to be the smallest toxic species. Inhibiting the formation of β-sheet-rich oligomers and fibrils is considered as the primary therapeutic strategy for AD. Previous studies reported that fullerene derivatives strongly inhibit Aβ fibrillation. However, the underlying inhibitory mechanism remains elusive. As a first step to understand fullerene-modulated full-length Aβ aggregation, we investigated the conformational ensemble of the Aβ1-42 dimer with and without 1,2-(dimethoxymethano)fullerene (DMF) - a more water-soluble fullerene derivative - by performing a 340 ns explicit-solvent replica exchange molecular dynamics simulation. Our simulations show that although disordered states are the most abundant conformations of the Aβ1-42 dimer, conformations containing diverse extended β-hairpins are also populated. The first most-populated β-hairpins involving residues L17-D23 and A30-V36 strongly resemble the engineered β-hairpin which is a building block of toxic Aβ oligomers. We find that the interaction of DMFs with Aβ peptides greatly impedes the formation of such β-hairpins and inter-peptide β-sheets. Binding energy analyses demonstrate that DMF preferentially binds not only to the central hydrophobic motif LVFFA of the Aβ peptide as suggested experimentally, but also to the aromatic residues including F4 and Y10 and the C-terminal hydrophobic region I31-V40. This study reveals a complete picture of the inhibitory mechanism of full-length Aβ1-42 aggregation by fullerenes, providing theoretical insights into the development of drug candidates against AD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27091578     DOI: 10.1039/c6cp01014h

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  15 in total

1.  The membrane axis of Alzheimer's nanomedicine.

Authors:  Yuhuan Li; Huayuan Tang; Nicholas Andrikopoulos; Ibrahim Javed; Luca Cecchetto; Aparna Nandakumar; Aleksandr Kakinen; Thomas P Davis; Feng Ding; Pu Chun Ke
Journal:  Adv Nanobiomed Res       Date:  2020-11-26

2.  Amphiphilic surface chemistry of fullerenols is necessary for inhibiting the amyloid aggregation of alpha-synuclein NACore.

Authors:  Yunxiang Sun; Aleksandr Kakinen; Chi Zhang; Ye Yang; Ava Faridi; Thomas P Davis; Weiguo Cao; Pu Chun Ke; Feng Ding
Journal:  Nanoscale       Date:  2019-06-20       Impact factor: 7.790

3.  Modulating protein amyloid aggregation with nanomaterials.

Authors:  Bo Wang; Emily H Pilkington; Yunxiang Sun; Thomas P Davis; Pu Chun Ke; Feng Ding
Journal:  Environ Sci Nano       Date:  2017-07-28

4.  Molecular dynamics simulations of amyloid-β peptides in heterogeneous environments.

Authors:  Yuhei Tachi; Satoru G Itoh; Hisashi Okumura
Journal:  Biophys Physicobiol       Date:  2022-04-02

5.  αB-Crystallin Chaperone Inhibits Aβ Aggregation by Capping the β-Sheet-Rich Oligomers and Fibrils.

Authors:  Yunxiang Sun; Feng Ding
Journal:  J Phys Chem B       Date:  2020-10-29       Impact factor: 2.991

6.  Molecular Mechanism and Kinetics of Amyloid-β42 Aggregate Formation: A Simulation Study.

Authors:  Viet Hoang Man; Xibing He; Beihong Ji; Shuhan Liu; Xiang-Qun Xie; Junmei Wang
Journal:  ACS Chem Neurosci       Date:  2019-11-11       Impact factor: 4.418

7.  Molecular Dynamics Simulations Reveal the Modulated Mechanism of STING Conformation.

Authors:  Li Chen; Shuang Zhao; Yanyan Zhu; Yongsheng Liu; Huiyu Li; Qingjie Zhao
Journal:  Interdiscip Sci       Date:  2021-06-17       Impact factor: 2.233

Review 8.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

9.  Spontaneous Formation of β-sheet Nano-barrels during the Early Aggregation of Alzheimer's Amyloid Beta.

Authors:  Yunxiang Sun; Aleksandr Kakinen; Xulin Wan; Niamh Moriarty; Cameron P J Hunt; Yuhuan Li; Nicholas Andrikopoulos; Aparna Nandakumar; Thomas P Davis; Clare L Parish; Yang Song; Pu Chun Ke; Feng Ding
Journal:  Nano Today       Date:  2021-03-13       Impact factor: 18.962

10.  Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.

Authors:  Baiping Ren; Mingzhen Zhang; Rundong Hu; Hong Chen; Manli Wang; Yufeng Lin; Yan Sun; Lingyun Jia; Guizhao Liang; Jie Zheng
Journal:  ACS Omega       Date:  2017-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.